Results 41 to 50 of about 1,885,895 (335)

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Acta Dermato-Venereologica
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation.
Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo   +5 more
doaj   +1 more source

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer

Acta Médica Portuguesa, 2019
The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors.
Andreia Tereso, Luís Carreto, Manuela Baptista, Maria Amélia Almeida   +3 more
doaj   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

Revista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles   +8 more
doaj   +1 more source

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.

Cancer Research, 2019
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non-small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative example of the successes in targeting oncogene addiction in cancer and the role of ...
A. Murtuza, Ajaz Bulbul, J. Shen, P. Keshavarzian, B. Woodward, F. Lopez-Diaz, S. Lippman, H. Husain   +7 more
semanticscholar   +1 more source

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Šmídová, Veronika, Michálek, Petr, Goliášová, Zita, Eckschlager, Tomáš, Hodek, Petr, Adam, Vojtěch, Heger, Zbyněk   +6 more
openaire   +3 more sources

Nilotinib-Associated Destructive Thyroiditis

Case Reports in Endocrinology, 2015
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala, Monica D. Schwarcz, Michael D. Goldberg, Guy Valiquette, Irene A. Weiss   +4 more
doaj   +1 more source

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Haematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani   +9 more
doaj   +1 more source

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Archives of Pathology & Laboratory Medicine, 2013
Objective To establish evidence-based recommendations for the molecular analysis of lung cancers that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be ...
N. Lindeman, P. Cagle, M. Beasley, D. Chitale, S. Dacic, G. Giaccone, R. Jenkins, D. Kwiatkowski, J. Saldivar, J. Squire, E. Thunnissen, M. Ladanyi   +11 more
semanticscholar   +1 more source

Start selective and rigidify: The discovery path towards a next generation of EGFR tyrosine kinase inhibitors.

Journal of Medicinal Chemistry, 2019
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
H. Engelhardt, Dietrich Böse, M. Petronczki, D. Scharn, G. Bader, A. Baum, A. Bergner, Eugene Chong, Sandra Döbel, G. Egger, Christian Engelhardt, P. Ettmayer, Julian E. Fuchs, Thomas Gerstberger, N. Gonnella, A. Grimm, Elisabeth Grondal, N. Haddad, Barbara Hopfgartner, Roland Kousek, M. Krawiec, M. Kriz, Lyne Lamarre, Joyce C. Leung, M. Mayer, Nitinchandra D. Patel, Biljana Peric Simov, J. T. Reeves, Renate Schnitzer, Andreas Schrenk, Bernadette Sharps, F. Solca, Heinz Stadtmüller, Z. Tan, Tobias Wunberg, A. Zöphel, D. McConnell   +36 more
semanticscholar   +1 more source

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +3 more sources